Fundraising FoxArmgo
1 known investors
Find your way into Armgo
Sign up to find every way you can get introduced to Armgo
- Your email: who you already know at Armgo, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Armgo team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
ARMGO develops a novel class of therapeutics called Rycals that target ryanodine receptors (RyRs) to correct calcium channel dysfunction in serious diseases with high unmet need. Its lead candidate, Surlorian, is being developed for heart failure by addressing an underlying driver of disease progression.
Investors · 1
Frequently asked questions
- What does Armgo do?
- ARMGO develops a novel class of therapeutics called Rycals that target ryanodine receptors (RyRs) to correct calcium channel dysfunction in serious diseases with high unmet need. Its lead candidate, Surlorian, is being developed for heart failure by addressing an underlying driver of disease progression.
- Who are Armgo's investors?
- Armgo's investors include Aisling Capital.